Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth

vs
industry
vs
history
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.

Ratios

vs
industry
vs
history
PE Ratio 19.14
PJP's PE Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PJP: 19.14 )
Ranked among companies with meaningful PE Ratio only.
PJP' s PE Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 19.14
PE Ratio without NRI 19.14
PJP's PE Ratio without NRI is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PJP: 19.14 )
Ranked among companies with meaningful PE Ratio without NRI only.
PJP' s PE Ratio without NRI Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 19.14
PB Ratio 2.99
PJP's PB Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PJP: 2.99 )
Ranked among companies with meaningful PB Ratio only.
PJP' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 2.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.91
PJP's Dividend Yield % is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. PJP: 0.91 )
Ranked among companies with meaningful Dividend Yield % only.
PJP' s Dividend Yield % Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.91

More Statistics

Short Percentage of Float0.00%
52-Week Range $53.72 - 68.56
Shares Outstanding (Mil)12,450,000.00
» More Articles for PJP

Headlines

Articles On GuruFocus.com
An Important achievement for Elbit Systems in the field of ground intelligence: Elbit Systems Awarde May 28 2017 
CN receives strike notice from union representing train conductors in Canada May 27 2017 
AT&T Invests Nearly $30 Million Over 3-Year Period to Enhance Local Networks in Flint May 27 2017 
HSBC: High-Yield Bank Stock With a 5.9% Dividend and Growth From Emerging Markets May 27 2017 
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against KBR, Inc May 26 2017 
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against T May 26 2017 
EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Vince Holding Co May 26 2017 
Stocks That Fell to 3-Year Lows in the Week of May 26 May 27 2017 
Barrick Gold SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds May 26 2017 
PCM SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS May 26 2017 

More From Other Websites
Performance of Merck’s Diabetes Portfolio in 1Q17 May 24 2017
Understanding Allergan’s Valuation after the 1Q17 Results May 11 2017
Gilead Sciences Posts Mixed Q1 Results: ETFs in Focus May 03 2017
Bristol-Myers Squibb’s 1Q17 Estimates: Virology Segment Apr 26 2017
Johnson & Johnson’s 1Q17 Segment-by-Segment Performance Apr 20 2017
Johnson & Johnson’s 1Q17 Estimates: Pharmaceuticals Segment Apr 13 2017
Analyzing the Performance of Abbott Laboratories in 1Q17 Apr 11 2017
ETF Flyers: Pharmaceuticals Apr 07 2017
Performance of Merck & Co. Stock in 1Q17 Apr 07 2017
These Key Product Developments Could Help Pfizer Apr 04 2017
Recent Developments at Eli Lilly Apr 03 2017
How Eli Lilly’s Business Segments Performed in 2016 Mar 30 2017
Bausch & Lomb Continues to be Key Growth Driver for Valeant Mar 24 2017
New Product Launches May Boost Valeant’s Dermatology Revenue Mar 23 2017
Relistor May Be Solid Growth Opportunity for Valeant in 2017 Mar 22 2017
Billionaire Investor, Millionaire Mistakes Mar 20 2017
Trump, Biogen and Amgen Hammer Healthcare ETFs Mar 20 2017
Should You Buy Pharma ETFs Now? Mar 15 2017
[$$] Drug Stocks Look Ready To Move Higher Mar 15 2017
Trump’s ‘Obamacare Lite’ presents opportunities and perils for investors Mar 09 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK